Toxicokinetics and Immunogenicity of CBX129801, a Pegylated C-Peptide Drug for Type 1 Diabetes Replacement Therapy, in Sprague Dawley Rats

Purpose

To assess toxicokinetics (TK) and immunogenicity ofCBX129801 in rats after subcutaneous (SC) injections
for 4 weeks (5 doses) with 4-week recovery period